Actelion wins another approval for Opsumit

The European Commission has approved Actelion's (ALIOF +1.6%) Opsumit for PAH as a monotherapy or in conjunction with other PAH treatments. (PR)

The FDA approved the drug in October.

As FierceBiotech notes, the approvals should give the company a bit of a cushion as Tracleer goes off patent in 2015.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs